BioCryst Pharmaceuticals Inc. (BCRX) Lowered to “Sell” at Zacks Investment Research
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
A number of other research firms have also recently weighed in on BCRX. Piper Jaffray Cos. raised shares of BioCryst Pharmaceuticals from a neutral rating to an overweight rating and boosted their target price for the stock from $5.00 to $8.00 in a research note on Friday, August 12th. FBR & Co reaffirmed a buy rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 8th. HC Wainwright reaffirmed a buy rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. JPMorgan Chase & Co. reaffirmed a hold rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Finally, JMP Securities cut shares of BioCryst Pharmaceuticals from an outperform rating to a market perform rating in a research note on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of Hold and a consensus target price of $8.22.
BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 1.876% during mid-day trading on Tuesday, hitting $4.615. 141,013 shares of the company were exchanged. BioCryst Pharmaceuticals has a 12-month low of $1.63 and a 12-month high of $12.28. The company’s 50-day moving average is $4.43 and its 200 day moving average is $3.52. The company’s market capitalization is $340.13 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. The firm had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $3.92 million. BioCryst Pharmaceuticals had a negative net margin of 285.24% and a negative return on equity of 187.98%. The company’s revenue was down 81.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.06 earnings per share. Analysts expect that BioCryst Pharmaceuticals will post ($1.03) EPS for the current year.
In related news, VP Yarlagadda S. Babu sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $4.06, for a total transaction of $121,800.00. Following the sale, the vice president now directly owns 111,428 shares in the company, valued at approximately $452,397.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Thomas R. Staab II sold 5,864 shares of the company’s stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $5.18, for a total transaction of $30,375.52. Following the sale, the insider now owns 128,745 shares in the company, valued at $666,899.10. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by company insiders.
Several hedge funds have recently made changes to their positions in BCRX. Schwab Charles Investment Management Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 1.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 245,729 shares of the biotechnology company’s stock worth $698,000 after buying an additional 3,528 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $180,000. Highbridge Capital Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $376,000. RTW Investments LLC boosted its stake in shares of BioCryst Pharmaceuticals by 13.3% in the second quarter. RTW Investments LLC now owns 2,237,066 shares of the biotechnology company’s stock worth $6,353,000 after buying an additional 263,134 shares during the last quarter. Finally, VHCP Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 78.5% in the second quarter. VHCP Management LLC now owns 1,005,104 shares of the biotechnology company’s stock worth $2,854,000 after buying an additional 442,161 shares during the last quarter. Institutional investors own 70.34% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.